conact-icon

07758 739185

email-icon

info@ctrtrust.co.uk

News

Immunotherapy treatment discovered that can have long-term survival benefit for Uveal melanoma
February 28th, 2024

Immunotherapy treatment discovered that can have long-term survival benefit for Uveal melanoma

At CTRT, we are dedicated to finding better ways of treating cancer, as well as detecting, monitoring and understanding how cancer develops, particularly in rare cancers that don’t receive research funding elsewhere.

One of our trustees, Professor Paul Nathan has led a clinical trial at the Mount Vernon Cancer Centre, and has discovered a more successful way of treating Uveal melanoma.

Uveal melanoma is a rare, but often high risk, type of cancer of the eye that frequently spreads to other parts of the body (particularly the liver). Unlike skin melanoma, once the cancer has spread, it does not respond very well to so-called immune checkpoint inhibitors, a type of cancer treatment that uses the body’s own immune system to recognize and fight off cancer cells. However, data from the clinical trial led by Professor Paul Nathan at the Mount Vernon Cancer Centre indicated that another type of immunotherapy can have long-term survival benefit in patients with metastatic uveal melanoma, a form of the disease that has spread.

The immunotherapy used in the trial, tebentafusp, works by bringing cells of the immune system close to the melanoma cells, effectively directing the immune cells to kill the cancer cells. Tebentafusp can perform this bridging role because it was designed as a ‘bispecific fusion protein’, which means that it latches on to pieces of a particular protein that melanoma cells have in abundance on their surface, as well as to a protein called CD3, that is present on T cells, a type of immune cell that is particularly efficient at killing cancer cells.

Initial reports showed that, at 1 year, tebentafusp improved the survival of patients with metastatic uveal melanoma, and the latest trial results which have been published recently in the New England Journal of Medicine, showed that the benefit is still seen at 3 years.

Nearly 400 patients, all of whom had previously untreated metastatic uveal melanoma, took part in the trial. They were randomly assigned to receive either tebentafusp or another treatment — a checkpoint inhibitor (pembrolizumab or ipilimumab) or chemotherapy (dacarbazine). At 3 years, more of the patients who had been given tebentafusp were still alive (27%) compared with the patients receiving any of the other treatments (18%). The side effects of tebentafusp were similar to those seen previously which included a rash, fever/chills, itching and low blood pressure. Very few patients receiving any of the drugs had to stop treatment, and there were no treatment-related deaths during the trial.

Tebentafusp clearly presents an advantage over current treatments for Uveal melanoma but unfortunately, it does not offer a cure at present. Moreover, tebentafusp only works in a subset of patients — making broadening tebentafusp’s potential benefit another priority.

Nevertheless, the future for tebentafusp, perhaps in combination with other treatments, looks very promising. Professor Nathan is leading an international trial due to begin in summer 2024 that will look at whether tebentafusp, if given after the primary treatment to tackle the melanoma in the eye, can reduce the number of patients who relapse with metastatic disease. This clinical trial will take place at many centres throughout Europe and North America and is being run by the European Organisation for Research and Treatment of Cancer.

The trial was run and funded by Immunocore, with some staffing costs at Mount Vernon Hospital supported by CTRT.

The Cancer Treatment and Research Trust continues to support Professor Nathan’s research thanks to your generosity. You can donate towards our melanoma research here

Research paper published in the New England Journal December 2023: Hassel, J.C. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023 Dec 14;389(24):2256-2266. doi: 10.1056/NEJMoa2304753.

Related Posts

Hide, Seek, Treat: Outsmarting Gestational Trophoblastic Neoplasia with Immunotherapy
August 14th, 2026 By ctrt_admin

Hide, Seek, Treat: Outsmarting Gestational Trophoblastic Neoplasia with Immunotherapy

Gestational trophoblastic neoplasia (GTN) (a form of Gestational Trophoblastic Disease) is a type of malignant (cancerous) tumour that develops during or after pregnancy from cells that would normally form the placenta – the organ that feeds the growing baby. GTN is rare and also highly unusual. Whilst all other cancers grow from the body’s own cells, GTN comes from cells that belong to the placenta which genetically is part of the fetus. Usually, cells in the body that aren’t ‘self’ are recognised as foreign & destroyed by the immune system. However, special mechanisms come in to play during pregnancy, which limits immune reactions to prevent the mother’s immune system destroying the baby and placenta. As is typical of cancers, however, GTN can hijack these mechanisms to avoid being targeted by the immune system, enabling it to grow and spread to other parts of the mother’s body. On the flip side, GTN responds much better than other cancers to a certain type of immunotherapy, with a cure rate of around 75%. Immunotherapy works by stimulating the body's own immune system to target and kill cancer cells, which begs the obvious question: how does this treatment expose the tumour to attack by the immune system? This is precisely the topic that Yiming Guan, a PhD student funded by the Cancer Treatment & Research Trust, is researching. Together with his coworkers, and under the supervision of Dr Ehsan Ghorani, Yiming aims to investigate the immune cell ‘landscape’ of GTN, in essence creating a directory of the types and locations of immune cells around the tumour before and after immunotherapy. The current thinking is that, in the absence of immunotherapy, GTN tumour cells send instructions to a certain type of immune cell (a CD4 T cell), telling it to adopt a more tolerant role and to talk its comrades out of mounting an immune attack; immunotherapy, however, intercepts these messages so that CD4 cells enlist in and coordinate an immune cell army to destroy the tumour cells. Precisely what determines whether these T cells behave as peacekeepers or soldiers, though, isn’t fully understood. In the 3-year PhD project funded by CTRT, Yiming and his fellow lab mates will use state-of-the-art ‘multi-omics’ techniques to generate huge amounts of information about the biological molecules that are present in GTN tumours, and immune cells from tissue samples taken from untreated patients and from patients given the immunotherapy drug Pembrolizumab. Changes in the amounts of particular molecules and/or their whereabouts within individual tumour and immune cells could give us more insight into the mechanisms that militarize T cells against the tumours. Since GTN responds so well to immunotherapy, these studies could uncover important principles that might help to improve this treatment for other, more common cancers that do not usually respond well to treatment.
Read More read more
New Guidelines for Gestational Trophoblastic Disease
November 19th, 2025 By ctrt_admin

New Guidelines for Gestational Trophoblastic Disease

Gestational trophoblastic disease (GTD) comprises a rare group of pregnancy-related tumours, ranging from premalignant forms, including partial and complete hydatidiform moles (molar pregnancies), to malignant types (referred to as gestational trophoblastic neoplasia (GTN)), which include invasive mole, choriocarcinoma, placental site trophoblastic tumours and epithelioid trophoblastic tumours. Although uncommon, GTD affects around 220,000 women globally each year, with 22,000 developing GTN. In a recent podcast, the Editor-in-Chief of the International Journal of Gynecological Cancer, Dr Pedro Ramirez, sat down with CTRT’s Chair of Trustee’s Professor Michael Seckl and Dr Christianne Lok, two leading international experts in gynaecologic oncology, to discuss Practical Guidelines for the Treatment of GTD: Collaboration of the European Organization for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynecologic Oncology (ESGO)-Gynecologic Cancer Intergroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD), recently published in the Journal of Clinical Oncology. Developed by 53 specialists across 31 countries, these guidelines represent the most comprehensive global consensus to date. One key topic of discussion in the podcast was the importance of specialized GTD centres. The new guidelines define clear criteria for such centres, with the hope of improving access to expert care worldwide. Even though these tumours are uncommon, centralization of care, the experts explained, improves outcome, as shown in studies of other cancers and rare diseases. The experts also emphasized that careful history-taking should always be part of the diagnostic process, regardless of any latest developments. Abnormal bleeding, severe nausea or abdominal pain can point to GTD, but confirmation relies on ultrasonography, measurement of human chorionic gonadotropin (hCG; a pregnancy hormone often raised in GTD), and most importantly, tissue analysis; genetic testing can also help. The guidelines also include flowcharts to guide doctors through diagnostic dilemmas. Another focus of the guidelines is treatment approaches. For low-risk GTN, single-agent chemotherapy with either methotrexate or actinomycin D is highly effective; the choice of drug often depends on local healthcare systems and patient preference. For high- and ultra-high-risk patients, low-dose induction regimens are often advised prior to more intensive combination chemotherapy treatment to avoid dangerous complications. The experts highlighted how immunotherapy has emerged as a transformative treatment option, particularly for patients who previously faced poor outcomes, as well as offering new hope for patients with very rare subtypes such as placental site and epithelioid trophoblastic tumours. Finally, the guidelines emphasize individualized follow-up. The accompanying flowcharts help clinicians tailor surveillance, while recent evidence has suggested that follow-up after partial and complete moles could potentially be shortened once hCG levels normalize — welcome news for women hoping to conceive again. The experts also considered fertility in their discussion of disease recurrence in the podcast. These new guidelines represent a milestone for GTD care, paving the way for better support and outcomes for patients worldwide. Listen to the full podcast with Professor Seckl and Dr Lok here.
Read More read more
The Cancer Treatment and Research Trust
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.